Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.50 |
| ▸ | FAP | Q12884 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3359409 | 1.00 | DPP4 (0.50) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL31448430 | 0.97 | DPP4 (0.48) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL30552684 | 0.97 | DPP4 (0.48) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL29615762 | 0.96 | DPP4 (0.46) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL31497255 | 0.93 | DPP4 (0.44) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL29411145 | 0.93 | DPP4 (0.44) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL29816377 | 0.93 | DPP4 (0.44) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL10793052 | 0.87 | PREP (0.44) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL10793068 | 0.87 | PREP (0.44) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL13267310 | 0.86 | DPP4 (0.52) | DPP4DPP8DPP9FAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374112-A1 | Bioactive Collagen Peptides, Method Of Production Thereof, And Use Thereof | BDC CAPITAL INC. (CA) | 2023-11-23 | — | — | US | claimed |
| WO-2022067445-A1 | BIOACTIVE COLLAGEN PEPTIDES, METHOD OF PRODUCTION THEREOF, AND USE THEREOF | CORPORATION GENACOL CANADA INC. (CA) | 2022-04-07 | — | — | WO | claimed |
| EP-0142231-B1 | PROCESS FOR PRODUCING SEQUENTIAL POLYAMINO ACID RESIN | NITTO BOSEKI CO., LTD. (JP) | 1987-11-11 | — | — | EP | claimed |
| EP-0142231-A1 | Process for producing sequential polyamino acid resin | NITTO BOSEKI CO., LTD. (JP) | 1985-05-22 | — | — | EP | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260115261-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | SUSTAIN HOLDINGS LLC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12551525-B2 | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | SUSTAIN HOLDINGS, LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-12419936-B2 | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | SUSTAIN HOLDINGS, LLC (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250268974-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF | SUSTAIN HOLDINGS, LLC | 2025-08-28 | — | — | US | disclosed |
| US-20250213641-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF | SUSTAIN HOLDINGS, LLC | 2025-07-03 | — | — | US | disclosed |
| CN-119541903-B | Method for identifying effectiveness of gastrodia elata extract in preventing and treating parkinsonism | 中国农业科学院农产品加工研究所 | 2025-06-13 | — | — | CN | disclosed |
| US-20250188139-A1 | VEGF-C MUTEINS FOR SELECTIVE LYMPHATIC STIMULATION | YALE UNIVERSITY (US) | 2025-06-12 | — | — | US | disclosed |
| US-11390662-B2 | Collagen mimics | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2022-07-19 | — | — | US | disclosed |
| US-11389513-B2 | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | SUSTAIN HOLDINGS, LLC (US) | 2022-07-19 | — | — | US | disclosed |
| WO-2022067445-A1 | BIOACTIVE COLLAGEN PEPTIDES, METHOD OF PRODUCTION THEREOF, AND USE THEREOF | CORPORATION GENACOL CANADA INC. (CA) | 2022-04-07 | — | — | WO | disclosed |
| EP-3450556-B1 | PEPTIDE INHIBITING COLONIZATION BY PATHOGENIC BACTERIA, AND COLONIZATION INHIBITOR INCLUDING SAME | UNIV OSAKA (JP) | 2022-03-23 | — | — | EP | disclosed |
| EP-3958889-A2 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF | Sustain Holdings, LLC (US) | 2022-03-02 | — | — | EP | disclosed |
| EP-2794663-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2014-10-29 | — | — | EP | disclosed |
| CN-103665170-A | Peptide therapeutic conjugates and uses thereof | ANGIOCHEM INC | 2014-03-26 | — | — | CN | disclosed |
| WO-2010063124-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | DPP4 43/4885DPP8 41/4885DPP9 59/4885 |
| US-20260115261-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | COL1A1, COL2A1, COL14A1 | DPP4 852/4885DPP8 2138/4885DPP9 1537/4885 |
| US-12551525-B2 | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | COL2A1, COL14A1, COL1A1 | DPP4 1566/4885DPP8 2253/4885DPP9 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.